Johns Hopkins Develops Epigenetic Instability Cancer Test
Analysis based on 7 articles · First reported Feb 02, 2026 · Last updated Feb 04, 2026
This medical breakthrough by the Johns Hopkins Kimmel Cancer Center could significantly impact the medical diagnostics market by introducing a more robust and universal method for early cancer detection. It has the potential to reduce false positives from existing tests like PSA, leading to more efficient and accurate patient triaging.
Researchers at the Johns Hopkins Kimmel Cancer Center have developed a novel liquid biopsy method for early-stage cancer detection, utilizing a new metric called the Epigenetic Instability Index (EII). This approach measures random variations in DNA methylation patterns, rather than absolute levels, proving more effective in distinguishing early-stage lung and breast cancers from healthy individuals. Led by Hariharan Easwaran and co-led by Thomas Pisanic, with key contributions from Sara-Jayne Thursby, the study's findings were published in Clinical Cancer Research and presented at the 2024 AACR meeting. The EII demonstrated 81% sensitivity at 95% specificity for stage 1A lung adenocarcinoma and 68% sensitivity at 95% specificity for early-stage breast cancer, with promising results for colon, brain, pancreatic, and prostate cancers. Supported by the United States===National Institutes of Health, United States===National Cancer Institute, United States===National Institute on Aging, and United States===National Institute of Environmental Health Sciences, this innovation could complement existing screening tools and improve diagnostic accuracy, potentially reducing unnecessary invasive procedures.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard